When Wayne State University researcher Dr. Zhou-Hua Pan placed a light-sensitive green algae protein into blind mice in 2006, he was amazed to find that it restored the subjects' vision almost immediately.

Fast forward to 2015, the year of many great things, and that protein is now the subject of a forthcoming set of human trials aimed at unveiling a potential cure for blindness in humans.

RetroSense Therapeutics, the company who leased the research from Dr. Zhou-Hua Pan and recently received approval from the Food and Drug Administrationto administer human trials, is expected to begin testing the protein on 15 patients by the end of the year. According to Singularity Hub, channelrhodopsin-2 is the same "magical switch" protein already famous for its ability to "turn a gentle mouse aggressive, shut down obsessive grooming behavior, and implant false memories in unsuspecting mice."

READ MORE AT COMPLEX. COM

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites